Ranolazine
Catalog No.S1799 Synonyms: CVT 303, RS 43285-003
Molecular Weight(MW): 427.54
Ranolazine is a calcium uptake inhibitor via the sodium/calcium channel, used to treat chronic angina.
Purity & Quality Control
Choose Selective Calcium Channel Inhibitors
Biological Activity
| Description | Ranolazine is a calcium uptake inhibitor via the sodium/calcium channel, used to treat chronic angina. | |
|---|---|---|
| Targets |
|
|
| In vitro |
Ranolazine is found to bind more tightly to the inactivated state than the resting state of the sodium channel underlying I(NaL), with apparent dissociation constants K(dr)=7.47 mM and K(di)=1.71 mM, respectively. Ranolazine at 5 mM and 10 mM reversibly shortens the duration of TCs and abolishes the after contraction.[1] Ranolazine inhibits the late component of INa and attenuates prolongation of action potential duration when late INa is increased, both in the absence and presence of IK-blocking drugs. Ranolazine (10 mM) reduces by 89% the 13.6-fold increase in variability of APD caused by 10 nM ATX-II. [2] |
|
| In vivo | Ranolazine significantly and reversibly shortens the action potential duration (APD) of myocytes stimulated at either 0.5 or 0.25 Hz in a concentration-dependent manner in left ventricular myocytes of dogs. [1] Ranolazine (10 mM) significantly increases glucose oxidation 1.5-fold to 3-fold under conditions in which the contribution of glucose to overall ATP production is low (low Ca, high FA, with insulin), high (high Ca, low Fa, with pacing), or intermediate in working heart of rats. Ranolazine (10 mM) similarly increases glucose oxidation in normoxic Langendorff hearts (high Ca, low FA; 15 mL/min) of rats. Ranolazine significantly improves functional outcome in reperfused ischemic working hearts, which is associated with significant increases in glucose oxidation. [3] |
Protocol
Solubility (25°C)
| In vitro | DMSO | 86 mg/mL (201.15 mM) |
|---|---|---|
| Ethanol | 20 mg/mL (46.77 mM) | |
| Water | Insoluble |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 427.54 |
|---|---|
| Formula | C24H33N3O4 |
| CAS No. | 95635-55-5 |
| Storage | powder |
| Synonyms | CVT 303, RS 43285-003 |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02687269 | Not yet recruiting | Myocardial Stunning | Policlinico Universitario Agostino Gemelli | October 2016 | Phase 4 |
| NCT02829034 | Recruiting | Pulmonary Hypertension | University of Pennsylvania|Brigham and Womens Hospital|University of Maryland|Gilead Sciences | July 2016 | -- |
| NCT02817932 | Recruiting | Healthy Male Individuals | A.Menarini Asia-Pacific Holdings Pte Ltd | March 2016 | Phase 1 |
| NCT02653833 | Recruiting | Muscular Dystrophy | Cedars-Sinai Medical Center | December 2015 | Early Phase 1 |
| NCT02611596 | Not yet recruiting | Silent Myocardial Ischemia|Type 2 Diabetes | Walter Reed National Military Medical Center | November 2015 | -- |
| NCT02252406 | Recruiting | Stable Angina|Metabolic Syndrome | University of Florida | September 2015 | Phase 4 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
